Format

Send to

Choose Destination
Rev Neurol. 2009 Dec 1-15;49(11):581-6.

[A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy].

[Article in Spanish]

Author information

1
Instituto Nacional Neurologia y Neurocirugia de Cuba, Ciudad de la Habana, Cuba. arletygarcia@infomed.sld.cu

Abstract

INTRODUCTION:

To date no controlled, randomised studies with flexible dose regimens have been conducted in children with rolandic epilepsy, and therapy is therefore still empirical.

AIM:

To evaluate the effectiveness and safety of clobazam (CLB) compared with that of carbamazepine (CBZ) in rolandic epilepsy.

PATIENTS AND METHODS:

A prospective, open, controlled and randomised study was carried out to compare CBZ and CLB in children with rolandic epilepsy with a follow-up over a two-year period. A random sample of 45 patients was taken and 38 of them finished the study. A flexible dose regimen was indicated. Control of seizures, academic performance, behaviour, adherence to treatment, parents' degree of satisfaction and side effect profiles were all evaluated.

RESULTS:

Both drugs were equally effective at controlling seizures (94.1% of patients with CLB and 100% of those with CBZ were free of seizures on ending the study; p = 0.26). CLB controlled seizures earlier (33.3 +/- 45 days versus 48.2 +/- 72.3; p < 0.05) and had fewer side effects than CBZ (side effects appeared in three patients with CLB and in eight of those on CBZ; p = 0). In two of the patients taking CBZ, the seizures got worse and a series of cognitive-behavioural complications also appeared.

CONCLUSIONS:

CBZ is an effective drug in rolandic epilepsy, but it may be associated with exacerbation of seizures as well as with cognitive-behavioural impairment. CLB in monotherapy seems to be an effective and better tolerated drug in this kind of epilepsy.

PMID:
19921623
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Viguera Editores, S. L.
Loading ...
Support Center